A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's Disease

New England Journal of Medicine

Volumn 337, Issue 15, 1997, Pages 1029-35

  Targan, Stephan R ^a   Hanauer, Stephen B ^b   Van Deventer, Sander J H ^c   Mayer, Llyod ^d   Present, Daniel H ^d   Braakman, Tanja ^e   DeWoody, Kimberly L ^e   Schaible, Thomas F ^e   Rutgeerts, Paul J ^f  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e CENTOCOR INC   (United States)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; RECOMBINANT FUSION PROTEINS; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030954732     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199710093371502     Document Type: Article

References (36)

1. Levine DS. Clinical features and complications of Crohn's disease. In: Targan S, Shanahan F, eds. Inflammatoty bowel disease: from bench to bedside. Baltimore: Williams & Wilkins, 1993:296-316.
2. Plevy SE, Targan SR. Specific management of Crohn's disease. In: Targan S, Shanahan F, eds. Inflammatory bowel disease: from bench to bedside Baltimore: Williams & Wilkins, 1993:582-609.
3. O'Brien HH, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology 1991;101: 39-46.
4. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995;332:292-7.
5. Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996;334: 841-8. [Erratum, N Engl J Med 1996;335:143.]
6. Brynskov J, Freund L, Rasmussen SN, et al. A placebo controlled, double blind randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989;321:845-50.
7. Feagan BG, McDonald JWD, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994;330:1846-51.
8. Jewell DP, Lennard-Jones JE, Cyclosporin Study Group of Great Britain and Ireland. Oral cyclosporin for chronic active Crohn's disease: a multicentre controlled trial. Eur J Gastroenterol Hepatol 1994;6:499-505.
9. Stange EF, Modigliani R, Peña AS, et al. European trial of cyclosporine in chronic active Crohn's disease: a 12 month study. Gastroenterology 1995;109:774-82.
10. Powrie F, Lesch MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994;1:553-62.
11. Neurath MF, Fuss I, Kelsall BL, Presky DH, Waegell W, Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-β-mediated oral tolerance. J Exp Med 1996;183:2605-16.
12. + T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med 1996;184:241-51.
13. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
14. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceicao-Silva F, Modlin RL. Cytokine patterns in the pathogenesis of human leishmaniasi's. J Clin Invest 1993;91:1390-5.
15. MacDonald TT, Hutchings P, Choy M-Y, Murch S, Cooke A. Tumor necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990;81:301-5.
16. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-9.
17. Mullin GE, Lazenby AJ, Harris ML, Bayless TM, James SP. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology 1992;102:1620-7.
18. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease: Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996;157:1261-70.
19. Maini RN, Elliott MJ, Brennan FM, Feldmann M. Beneficial effects of tumour necrosis factor-alpha (TNF-α) blockade in rheumatoid arthritis. Clin Exp Immunol 1995;101:207-12. [Erratum, Clin Exp Immunol 1995; 102:443.]
20. Cope AP, Londei M, Chu NR, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex: reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994;94:749-60.
21. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
22. van Dullemen HM, van Deventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
23. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979;77:843-6.
24. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994;106:287-96.
25. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
26. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7:251-9.
27. Siegel SA, Shealy DJ, Nakada MT, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995;7:15-25.
28. Agresti A. Categorical data analysis. New York: John Wiley, 1990:230-5.
29. Conover WJ. Practical nonparametric statistics. 2nd ed. New York: John Wiley, 1980:318-26.
30. Stronkhorst A, Tytgat GN, van Deventer SJ. CD4 antibody treatment in Crohn's disease. Scand J Gastroenterol Suppl 1992;194:61-5.
31. Emmrich J, Seyfarth M, Fleig WE, Emmrich F. Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody. Lancet 1991; 338:570-1.
32. Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflam Bowel Dis 1995;1:48-63.
33. Sachar DB. Maintenance therapy in ulcerative colitis and Crohn's disease. J Clin Gastroenterol 1995;20:117-22.
34. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993;5:1461-71.
35. McCabe RP, Woody J, van Deventer S, et al. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease. Gastrocnterology 1996;110:Suppl:A962. abstract.
36. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997;349:521-4.